CSL Limited (ASX: CSL)
The first blue chip ASX share to consider is CSL. It is one of the world’s leading biotechnology companies, comprising two businesses – CSL Behring and Seqirus. CSL Behring is the number one player in a global plasma therapies industry worth a massive US$30 billion per year. Whereas Seqirus is the number two player in the US$6 billion global influenza vaccines industry. CSL has been tipped for solid long term growth thanks to increasing demand for its therapies and its lucrative R&D pipeline.
UBS is positive on CSL. It currently has a buy rating and $330.00 price target on its shares.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$201.91 |
Change
-2.570(1.26%) |
Mkt cap ! $97.95B | |||
| Open | High | Low | Value | Volume |
| $203.58 | $204.20 | $200.66 | $234.0M | 1.155M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10 | $201.85 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $201.93 | 5 | 1 |
View Market Depth
| Last trade - 16.17pm 16/09/2025 (20 minute delay) ? |
| CSL (ASX) Chart |